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The purpose of this study was to estimate the risk and mortality of breast cancer recurrences 
in Swedish women, and to analyse changes over time and variations between patients in 
different risk groups. Such estimates are of key importance for modelling the cost-
effectiveness of different strategies for adjuvant treatment of breast cancer.  
 
The study was based on all women diagnosed with breast cancer in Stockholm County 
between 1985 and 2005. Information about dates for locoregional recurrences, metastatic 
relapses, new contralateral tumours and death was collected. Cox proportional hazard and 
Weibull regression models were used to estimate survival functions, where year of diagnosis 
(dived into 5-year intervals), were included as explanatory variables in the models. 
 
The risk of recurrences has decreased during the last 20 years for all three types of recurrence; 
for metastatic relapse the 5-year risk was reduced from 12.9% to 6.0% from 1985-90 to 2000-
2005 . Mortality has also been reduced, resulting in an increased 5-year survival from 52.6% 
to 64.1% after locoregional recurrence and from 10.4% to 15.5% for metastatic relapse. For 
contralateral tumours, with a 5-year survival rate of 74.6% in 1985-1990 and 78% 2000-2005, 
no significant increase was observed. Analysis of risk groups according to TNM classification 
showed large difference in the risk of metastatic breast cancer between the three defined 
groups, but small differences for the risk of locoregional recurrences and new contralateral 
tumours.  
 
The findings indicate that the early detection and new treatments have been successful in 
improving outcome for breast cancer patients and that it is important to use up-to-date 
information, when assessing the value of new treatment options. 
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 Introduction 
 
Breast cancer is the most common cancer in women. The incidence has increased in Sweden 
and many other countries during the last decades[1, 2]. Survival has also increased[2-5], and 
the total mortality from breast cancer has therefore remained relatively constant in many 
western countries[6, 7]. The overall 5- and 10-year survival of breast cancer in Sweden has 
increased from 65% and 53%, respectively, for those diagnosed 1964-1966 to 84% and 74%, 
respectively, for those diagnosed in the 1990’s[8]. The improved prognosis is likely a 
combination of early diagnosis[8-10] and improved treatment.  
 
Adjuvant treatment of early breast cancer reduce the risk of disease recurrence, and also the 
risk of new contralateral tumours[11, 12]. However, recurrences and new contralateral 
tumours are still common and new treatments reducing the risk of these events, or improve 
the prognosis when they occur, are therefore welcome. However, the introduction of new, and 
often costly, adjuvant treatments increases the cost of breast cancer care, and since breast 
cancer is a common disease this will have significant effect on the overall cancer care budget. 
It is therefore important to assess the value for money, i.e. the cost-effectiveness, of these new 
therapies in order to find the optimal use of them in clinical practice. The main benefit of 
adjuvant treatment is to reduce the risk of metastatic disease, but also locoregional 
recurrences and new contralateral tumours are important targets for improved therapy. The 
risks and consequences of these events are therefore key variables in models for assessing the 
cost-effectiveness of these treatments[13, 14].    
 
The risk of relapses also differs considerably between risk groups. Patients with large tumours 
and/or nodal involvement have higher risk of relapses[8]. The optimal adjuvant treatment may 
hence vary between risk groups and it is therefore also interesting to further explore variations 
in risk of relapses between groups of patients at different risk. The risk of recurrences/new 
contralateral tumours and the prognosis of patients having these events also vary over time as 
patient characteristics, diagnosis and treatment practices changes. This means that it is 
important to use relevant and up-to-date data when assessing the long-term benefits of new 
adjuvant treatments. It is also important to have specific Swedish data, since both treatment 
patterns and patients characteristics differ from those in other countries. We can thus not rely 
only on international studies if we like to have a reliable estimate of cost-effectiveness when 
new treatments are introduced for Swedish patients. 
 
Since the early 1980’s there has been several new treatments introduced. Tamoxifen, for 
example, was introduced in the 1970’s and the first aromatase inhibitor was introduced in mid 
1980’s. Taxanes were approved for adjuvant treatment in Europe in 2005 and trastuzumab in 
2006. Mammographic screening was introduced in Sweden in the mid 1980’s. It is currently 
recommended for women aged between 40 and 70 years in Sweden. Studies have indicated 
that the introduction of screening has reduced the total mortality from breast cancer. Baker et 
al estimated a reduction in incidence of breast cancer death in Sweden to -9 cases per 
100,000[15] and Duffy et al estimated that screening in seven Swedish counties resulted in a 
40-45% reduction in breast cancer mortality[16-18]. The benefit of the endocrine treatments, 
such tamoxifen or aromatase inhibitors, is now also widely acknowledged[19, 20]. It is 
therefore likely that the risk of having a recurrent breast cancer, and also the prognosis once 
diagnosed with a recurrent disease, have improved during the last 20 years. 
 The purpose of this study was to evaluate trends and variation between different risk groups in 
the risk and mortality of breast cancer recurrences and new contralateral tumours in Swedish 
women. Material and method 
 
The study was based on all women diagnosed with breast cancer in Stockholm County 
between 1985 and 2005. The women were identified from the cancer registry at the regional 
oncology centre in Stockholm. Information about age at diagnosis, TNM classification, and 
dates for recurrences, new contralateral tumours and death were collected. 
 
Data on four specific events was collected and used for the estimates: locoregional recurrence, 
metastatic disease (distant recurrence) contralateral cancer, and death. Risk is calculated as 
the probability of each event occurring for the first time. Time is measure from first diagnosis 
of the primary breast cancer. Mortality is analysed both as a first event (after primary 
diagnosis of breast cancer) and as conditional on a recurrence/contralateral tumour event. In 
the latter case, time to death is measured from diagnosis of the recurrence/contralateral 
tumour. The age of the patient is the age at the first diagnosis of the primary breast cancer.  
 
Risk variations over time 
Two models to compare risks over time are used: The Cox proportional hazard regression 
model and the Weibull regression models. The Cox model is suitable for analyzing the effect 
of risk factors, but does not give a functional form that can be used to calculate risks. The 
Weibull distribution, on the other hand, is suitable for modelling data with hazard rates that 
increase or decrease over time and can be used to derive a functional form of the risks.  
Separate regression models were estimated for the risks and the mortalities of locoregional 
recurrence, contralateral cancer and metastatic relapse. Date of diagnosis was dived into 5-
year intervals: 1985-1989, 1990-1994, 1995-1999 and 2000-, and were included as 
dichotomous explanatory variables in the regression models. The year of diagnosis 
corresponds to the year of the primary diagnosis in the estimation of risks of 
recurrences/contralateral cancer and the year of recurrence/contralateral cancer for the 
estimation of mortality. 
 
The Cox proportional hazard models are in general modelled as: 
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+ + + = , where X1 ... Xn are the explanatory variables and H0(t) is the 
baseline hazard at time t, representing the hazard for a person with the value 0 for all the 
explanatory variables. In our model, Xi corresponds to the dichotomous variables for the year 
interval of diagnosis, and H0(t) corresponds to the hazard function for patients diagnosed 
1985-1989. The hazard ratio is then obtained by dividing both sides of the equation above by 
H0(t) and taking logarithms. The hazard ratio shows the relative risk reduction. 
 
In the Weibull model it was thus assumed that time to recurrence and death (T) follows 
Weibull distributions. For t, a particular value of T, the Weibull survivor S(t) and hazard 
function λ(t) are defined according to: 
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negative parameters to be estimated. When p = 1, the Weibull distribution reduces to the 
exponential with a constant hazard rate and if p > 1 (p < 1) the hazard rate is monotonically 
increasing (decreasing) in t. To introduce covariates in the model, γ in the equations above is 
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Risk variations between patient groups 
Risk of the locoregional recurrence, metastatic relapse and new contralateral tumours were 
also assessed in different risk groups. The TNM classification was used to divide patients into three groups: Group 1 was patients with nodal involvement (T0-, N1-), group 2 those with 
large tumours without nodal involvement (T2-, N0) and group 3 were those with small 
tumours without nodal involvement (T0-1, N0). Separate analyses were also made for women 
below and above 55 years to explore differences between pre- and postmenopausal women. Results 
 
Information from 20,624 women diagnosed with breast cancer over the 20 year period was 
obtained. The mean age at diagnosis was 61 years and remained rather constant during the 
time interval. Screening did not seem to have an influence on the age at diagnosis. The mean 
follow-up time was 89 months. 23% of the women had had a recurrence or contralateral 
tumour and 33% had died during the follow-up period. 
 
Risk of recurrence/contralateral tumour 
Figures 1a-c in the appendix shows the Kaplan-Meier survival functions for risks of 
locoregional recurrence (figure 1a), metastatic relapse (figure 1b) and new contralateral 
tumour (figure 1c). Four separate curves, representing patients diagnosed 1985-1989, 1990-
1994, 1995-1999 or 2000-2004, are shown. The figures indicate a trend towards lower risk for 
patients diagnosed more recently. 
 
Table 1 presents the estimated parameter values in the Cox proportional hazard model. The 
coefficients for the explanatory variables show the differences in hazard rates between the 
various diagnosis year-intervals, compared to the first time period (i.e. 1985-1989). The 
hazard ratios are decreasing with year of diagnosis for all three types of events, which 
confirms that patients diagnosed recently have lower risk of recurrences/contralateral 
tumours. All hazard ratios are statistically significant (at a 0.05 level) except the risk for 
contralateral tumours in patients diagnosed between 1990 and 1994. 
 
The risk of metastatic recurrence was reduced with two thirds during the period, while for 
locoregional recurrence and contralateral tumour, where the risk is much smaller, the risk 
reduction was just over fifty per cent. 
.  
Table 1. Parameters estimated in the Cox proportional hazard model for risk of recurrence/contralateral 
tumour 
Events  Diagnosis year  Hazard ratio  p value  95% confidence interval 
1990-1994  0.875 0.043  0.769-0.996 
1995-1999  0.692 0.000  0.601-0.796 
Locoregional 
recurrence 
2000-2005  0.439 0.000  0.363-0.531 
        
1990-1994  0.690 0.000  0.630-0.756 
1995-1999  0.476 0.000  0.429-0.528 
Metastatic 
relapse 
2000-2005  0.333 0.000  0.289-0.385 
        
1990-1994  0.925 0.411  0.769-1.113 
1995-1999  0.598 0.000  0.477-0.751 
Contralateral 
tumour 
2000-2005  0.455 0.000  0.330-0.628 
 
Risks of recurrences/contralateral tumours were calculated from the estimated Weibull 
regression models. Table 2 presents the calculated risks for the different diagnosis year-
intervals. The results, for example, show that the 10-year risk of metastatic disease has 
decreased from 21.7% for patients diagnosed 1985-1989 to an estimated risk of 10.4% for 






Table 2. Estimated 5- and 10-year risks for recurrence/contralateral tumour (from Weibull regression 
models) 
  Locoregional recurrence  Metastatic relapse  Contralateral tumour 
Diagnosis 
year 
5-year risk  10-year risk  5-year risk  10-year risk  5-year risk  10-year risk 
1985-1989 6.4%  11.2%  12.9%  21.7%  2.6%  5.2% 
1990-1994   6.0%
*   10.5%
* 10.0%  17.0%    2.6%
*   5.3%
* 
1995-1999  5.5%    9.6%    8.1%  13.9%  1.7%  3.6% 
2000-2005  3.8%    6.7%    6.0%  10.4%  1.4%  2.8% 
* Not statistically significantly different from the result for the group diagnosed 1985-1989 
 
Figure 2a-f in the appendix shows the risks of locoregional recurrence (figure 2a-b), 
metastatic relapse (figure 2c-d) and new contralateral tumour (figure 2e-f) for patients under 
and over 55 years of age respectively, and for the three defined risk groups. There is a large 
difference in the risk of metastatic relapse between the risk groups, where small node negative 
tumours are associated with a much better prognosis. There were fairly small differences for 
locoregional recurrence and new contralateral tumour, and also the differences between pre- 
and postmenopausal women were small. 
 
Survival after primary breast cancer tumour 
Figure 3 in the appendix shows the Kaplan-Meier function for survival after primary breast 
cancer diagnosis. Four separate curves, representing patients diagnosed with the primary 
tumour 1985-1989, 1990-1994, 1995-1999 or 2000-2004, are again shown. The results 
indicate an increased survival from breast cancer over time, which is also confirmed in 
analyses using a Cox proportional hazard model. The coefficients for the explanatory 
variables, presented in table 3 shows, the differences in survival for the various diagnosis 
year-intervals compared to patients diagnosed between 1985 and 1989. 
 
Table 3. Parameters estimated in the Cox proportional hazard model for mortality after primary breast 
cancer diagnosis 
Diagnosis year  Hazard ratio  p value  95% confidence interval 
1990-1994  0.777 0.000  0.732-0.824 
1995-1999  0.700 0.000  0.655-0.749 
2000-2005  0.535 0.000  0.486-0.588 
 
Survival after recurrence/contralateral tumour 
Figure 4a-c in the appendix shows the Kaplan-Meier functions for survival after locoregional 
recurrence (figure 3a), metastatic relapse (figure 3b) and new contralateral tumour (figure 3c). 
Four separate curves, representing patients diagnosed with the recurrence/contralateral tumour 
1985-1989, 1990-1994, 1995-1999 or 2000-2004, are again shown. The curve for 
locoregional recurrence indicates a trend towards increased survival for patients diagnosed 
more recently. This trend can, however, only be observed for survival after metastatic relapse 
for those diagnosed after 1994 and could not be observed for contralateral tumours. 
 
Table 4 presents the estimated parameter values in the Cox proportional hazard model. The 
coefficients for the explanatory variables show the differences in survival between the various 
diagnosis year-intervals. The hazard ratios are decreasing with year of diagnosis for 
locoregional recurrence, which confirm that patients diagnosed with this event recently have 
increased survival compared to those diagnosed in the 1980’s. The hazard ratio in patients 
diagnosed after 1994 is statistically significant for metastatic relapse. 
 Table 4. Parameters estimated in the Cox proportional hazard model for mortality after 
recurrence/contralateral tumour 
Events  Diagnosis year  Hazard ratio  p value  95% confidence interval 
1990-1994  0.745 0.005  0.606-0.916 
1995-1999  0.590 0.000  0.474-0.736 
Locoregional 
recurrence 
2000-2005  0.556 0.000  0.430-0.718 
        
1990-1994  0.972 0.665  0.855-1.105 
1995-1999  0.880 0.049  0.774-0.999 
Metastatic 
relapse 
2000-2005  0.775 0.000  0.675-0.889 
        
1990-1994  1.037 0.206  0.639-1.101 
1995-1999  0.383 0.453  0.529-1.329 
Contralateral 
tumour 
2000-2005  0.690 0.170  0.406-1.173 
 
Survivals rates after recurrences/contralateral tumours were estimated from the Weibull 
regression models. Table 5 presents the survival for the different diagnosis year-intervals. 
There are very significant differences in survival after the different types of events. Most 
noticeable is the much lower 5 and 10 year survival after diagnosis of metastatic disease. 
However, both 5 and 10 year survival increased significantly over the period. Also after 
locoregional recurrence has the survival increased significantly over time. The 10-year 
survival increased from 28% for patients diagnosed 1985-1989 to 42% for patients diagnosed 
after 2000. 
 
Table 5. Estimated 5- and 10-year survival rates after recurrence/contralateral tumour (from Weibull 
regression models) 















1985-1989  52.6%  28.3%  10.4%    1.9%  74.6%   54.8%  
1990-1994 60.9%  37.7%    11.1%
*   2.1%
*   73.5%
*   53.1%
* 
1995-1999 64.8%  42.6%    12.7%
*   2.7%
*   75.2%
*   55.6%
* 
2000-2005 64.1%  41.7%    15.5%
   3.8%
   78.0%
*    59.9%
*  
* Not statistically significantly different from the result for the group diagnosed 1985-1989 Discussion 
 
We have in this study assessed variations over time and across risk groups in the risk and 
mortality of breast cancer recurrences/new contralateral tumours. Obtaining up-to-date 
information about the long-term risks is difficult since we do not have long-term data on 
patients recently diagnosed. We estimated Cox proportional hazard and Weibull regression 
models and included years of diagnosis as explanatory variables in the models. By using the 
Weibull regression models, we can use the most recent information from patients diagnosed 
during the last years to estimate the long-term risk for these patients, based on information 
from all patients in the sample. Although it is based on specific assumptions about the 
characteristics of the survival function, we think that this method provides a relevant 
estimation of the current risk of, and mortality from, recurrences. 
 
The findings show a reduction in the risk of and mortality from most types of breast cancer 
recurrences/new contralateral tumours over time. For metastatic disease, only patients 
diagnosed during the last 5-10 years showed an improved survival. The analysis also 
indicated that there was a large difference in the risk of metastatic relapse between the defined 
risk groups, but fairly small differences for locoregional recurrence and new contralateral 
tumours. Differences between pre- and postmenopausal women were also indicated to be 
small. No significant improvement in survival after contralateral tumours could be observed, 
but this may be due to the fairly small number of patients with contralateral tumours in the 
sample. 
 
We have in this study not attempted to explain causes for the reductions in risks and mortality. 
We can assume that these reductions are caused both by early diagnosis (and hence more 
tumours detected at an early stage) and improved surgery, radiotherapy and pharmacological 
treatments. A quantification of the contribution of various factors to the overall improved 
outcome is an interesting and important subject for future studies[21]. 
 
The calculation of risks and mortality of disease recurrences is important for the 
quantification of the benefits of treatments aimed at reducing the risk of recurrences. It is also 
important for evaluating treatments aimed at reducing the mortality of recurrences. The data 
show that risks of and mortality from most types of recurrences and new contralateral cancers 
have decreased during the last 20 years. This stresses the need to use relevant, up-to-date, 
information reflecting the current clinical practice in evaluations of the clinical and economic 
benefit of new therapies. The findings also indicate that the efforts made during the last 
decades to develop new treatments and ways to detect tumours early have been successful in 
improving outcome for breast cancer patients. It is, however, not possible to say anything 
about the value of individual intervention, or what the costs of the interventions are in relation 
to their benefits, i.e. their cost-effectiveness. 
 
The study was based on patients from only one county in Sweden. It is known that the risk 
and mortality of breast cancers varies between countries[22, 23], and sometimes also within 
countries. The exact risks and mortalities presented here may therefore not be representative 
of patients in other countries, but it is likely that the trend towards a reduced risk and 
mortality of recurrences identified here is transferable to many other settings. One of the 
implication of the findings, that it is important to use up-to-date information about risk and 
mortality of recurrences and new contralateral cancers for assessing the value of new 
treatments, is, however, relevant in most settings. 
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